dc.contributor.author | Mackay, A | |
dc.contributor.author | Burford, A | |
dc.contributor.author | Molinari, V | |
dc.contributor.author | Jones, DTW | |
dc.contributor.author | Izquierdo, E | |
dc.contributor.author | Brouwer-Visser, J | |
dc.contributor.author | Giangaspero, F | |
dc.contributor.author | Haberler, C | |
dc.contributor.author | Pietsch, T | |
dc.contributor.author | Jacques, TS | |
dc.contributor.author | Figarella-Branger, D | |
dc.contributor.author | Rodriguez, D | |
dc.contributor.author | Morgan, PS | |
dc.contributor.author | Raman, P | |
dc.contributor.author | Waanders, AJ | |
dc.contributor.author | Resnick, AC | |
dc.contributor.author | Massimino, M | |
dc.contributor.author | Garrè, ML | |
dc.contributor.author | Smith, H | |
dc.contributor.author | Capper, D | |
dc.contributor.author | Pfister, SM | |
dc.contributor.author | Würdinger, T | |
dc.contributor.author | Tam, R | |
dc.contributor.author | Garcia, J | |
dc.contributor.author | Thakur, MD | |
dc.contributor.author | Vassal, G | |
dc.contributor.author | Grill, J | |
dc.contributor.author | Jaspan, T | |
dc.contributor.author | Varlet, P | |
dc.contributor.author | Jones, C | |
dc.date.accessioned | 2018-03-27T10:50:00Z | |
dc.date.issued | 2018-05-14 | |
dc.identifier.citation | Cancer cell, 2018, 33 (5), pp. 829 - 842.e5 | |
dc.identifier.issn | 1535-6108 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/1612 | |
dc.identifier.eissn | 1878-3686 | |
dc.identifier.doi | 10.1016/j.ccell.2018.04.004 | |
dc.description.abstract | The HERBY trial was a phase II open-label, randomized, multicenter trial evaluating bevacizumab (BEV) in addition to temozolomide/radiotherapy in patients with newly diagnosed non-brainstem high-grade glioma (HGG) between the ages of 3 and 18 years. We carried out comprehensive molecular analysis integrated with pathology, radiology, and immune profiling. In post-hoc subgroup analysis, hypermutator tumors (mismatch repair deficiency and somatic POLE/POLD1 mutations) and those biologically resembling pleomorphic xanthoastrocytoma ([PXA]-like, driven by BRAF_V600E or NF1 mutation) had significantly more CD8+ tumor-infiltrating lymphocytes, and longer survival with the addition of BEV. Histone H3 subgroups (hemispheric G34R/V and midline K27M) had a worse outcome and were immune cold. Future clinical trials will need to take into account the diversity represented by the term "HGG" in the pediatric population. | |
dc.format | Print | |
dc.format.extent | 829 - 842.e5 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | CELL PRESS | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | CD8-Positive T-Lymphocytes | |
dc.subject | Humans | |
dc.subject | Glioma | |
dc.subject | DNA Polymerase III | |
dc.subject | Proto-Oncogene Proteins B-raf | |
dc.subject | Neurofibromin 1 | |
dc.subject | Survival Analysis | |
dc.subject | Mutation | |
dc.subject | Adolescent | |
dc.subject | Child | |
dc.subject | Child, Preschool | |
dc.subject | Female | |
dc.subject | Male | |
dc.subject | Neoplasm Grading | |
dc.subject | Chemoradiotherapy | |
dc.subject | Bevacizumab | |
dc.subject | Temozolomide | |
dc.title | Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2018-04-10 | |
rioxxterms.versionofrecord | 10.1016/j.ccell.2018.04.004 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2018-05 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Cancer cell | |
pubs.issue | 5 | |
pubs.notes | No embargo | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Glioma Team | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Glioma Team | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Glioma Team | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Glioma Team | |
pubs.publication-status | Published | |
pubs.volume | 33 | |
pubs.embargo.terms | No embargo | |
icr.researchteam | Glioma Team | |
dc.contributor.icrauthor | Mackay, Alan | |
dc.contributor.icrauthor | Jones, Chris | |